Social Media Ideas for Fbrx

Skye and Redx form new entity with $125M to advance fibrosis assets

Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new publ...

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

FIBRA Prologis (FBBPF) Q2 2026 Earnings Call Transcript

Barfresh outlines $23M-$26M FY2026 revenue outlook while targeting partial commissioning of Defiance plant by end of 202...

Barfresh Food Group, Inc. (BRFH) Q2 2026 Earnings Call Transcript

Inhibrx Biosciences: The Whole Story Rides On INBRX-106

BioRestorative Therapies Announces Reverse Stock Split

MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical…

Bruker (BRKR) Wagers On Fusion Energy While Wall Street Waits

Fenix Resources Limited (FEXRF) Q4 2026 Earnings Call Transcript

Biofrontera (BFRI) Q2 2026 Earnings Call Transcript

Gross margins expanded 920 basis points as restructured costs offset ITC lamp restrictions.

<![CDATA[FDA Approves Pasatru For Adults With Fibrodysplasia Ossificans Progressiva ]]>

First Breach Begins Trading on NASDAQ Under Ticker Symbol "FBDT"

Expanding American Defense Manufacturing Through Vertically Integrated Ammunition Production, Strategic Partnerships and Next Generation Drone Technologies

Fibra Danhos (GRFFF) Q2 2026 Earnings Call Transcript

argenx SE (ARGX) Forte Biosciences, Inc. - M&A Call - Slideshow

Fibra Mty, S.A.P.I. de C.V. (FMTYF) Q2 2026 Earnings Call Transcript

A Deeper Dive Into Design Therapeutics

BioArctic AB (publ) (BRCTF) Q2 2026 Earnings Call Transcript

Going Deeper On Disc Medicine

X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade)

Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript

Apitegromab awaits FDA decision on Sept. 30 for spinal muscular atrophy treatment.

FACTOR X Emerges from Stealth with Novel RNA - based Technology to Transform the Global Beauty Industry

FACTOR X is a newly launched longevity-focused beauty technology company developing a breakthrough cellular delivery platform designed to transform the anti-aging skincare industry...

Recursion (RXRX) Q2 2026 Earnings Call Transcript

AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.

OFIX 1H 2026: Limb Recon Leads, Spine Gains Traction, Europe’s Plot Twist

Orthofix looks like a duck: Smooth on the surface, paddling like hell underneath.

Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript

Cash runway extends to 2029 as ficerafusp alfa advances toward interim analysis.